Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13004014 | 0.77 | MIF (0.41) | KEAP1NFE2L2TSHRKDM4EALDH1A1 | |
| SCHEMBL23856563 | 0.71 | KEAP1 (0.70) | KEAP1NFE2L2TSHRKDM4EALDH1A1 | |
| SCHEMBL114292 | 0.71 | KEAP1 (0.46) | KEAP1NFE2L2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL243274 | 0.71 | ALDH1A1 (0.43) | TSHRKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL2920745 | 0.71 | KEAP1 (0.42) | KEAP1NFE2L2TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL4144906 | 0.70 | KEAP1 (0.49) | KEAP1NFE2L2KDM4EALDH1A1CASP1 | |
| SCHEMBL860929 | 0.70 | KEAP1 (0.57) | KEAP1NFE2L2TSHRKDM4EALDH1A1 | |
| SCHEMBL11999994 | 0.68 | GRM2 (0.32) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL23373287 | 0.68 | KEAP1 (0.46) | KEAP1NFE2L2KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL31651642 | 0.67 | PGK1 (0.37) | KEAP1NFE2L2KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1626045-B1 | PROCESSES FOR PRODUCING 3-SUBSTITUTED 2-CHLORO-5-FLUOROPYRIDINE OR SALT THEREOF | ASAHI GLASS CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7414136-B2 | Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt | ASAHI GLASS COMPANY, LIMITED (JP) | 2008-08-19 | — | — | US | disclosed |
| US-20060058529-A1 | Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt | ASAHI GLASS COMPANY, LIMITED (JP) | 2006-03-16 | — | — | US | disclosed |
| EP-1626045-A1 | PROCESSES FOR PRODUCING 3-SUBSTITUTED 2-CHLORO-5-FLUOROPYRIDINE OR SALT THEREOF | Asahi Glass Company, Limited (JP) | 2006-02-15 | — | — | EP | disclosed |
| US-5250548-A | Treating hypertension, heart failure | ABBOTT LABORATORIES (US) | 1993-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058529-A1 | Method for producing 3-substituted 2-chloro-5-fluoro-pyridine or its salt | ARL1, CBR3, ZC3HAV1L | KEAP1 1598/4885NFE2L2 2800/4885TSHR 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.